Release Date: 2024-06-12

Immunotherapy and Immunotherapeutic Drugs

Hasan Akkoc (Author)

Release Date: 2024-06-12

Immunotherapy is a type of treatment of a group of diseases, including cancer, that is based on the specific parts of the patient’s own immune system. Cancer immunotherapy aims to enable our immune system cells to target cancer cells and destroy them. Recently, cancer immunotherapy has become one of the most preferred drugs in cancer [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inImmunotherapy in Human Cancers
    First Page25
    Last Page32
    DOIhttps://doi.org/10.69860/nobel.9786053359388.3
    Page Count8
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing
    Immunotherapy is a type of treatment of a group of diseases, including cancer, that is based on the specific parts of the patient’s own immune system. Cancer immunotherapy aims to enable our immune system cells to target cancer cells and destroy them. Recently, cancer immunotherapy has become one of the most preferred drugs in cancer treatment. In cancer immunotherapy monoclonal antibodies, immune checkpoint inhibitors (ICI), cancer vaccines, oncolytic viruses, cytokine therapy and methods such as adoptive cell transfer come to the fore. Although these treatments are very promising for some types of cancer, they also have their own side effects.

    Hasan Akkoc (Author)
    Professor, Dicle University
    https://orcid.org/0000-0003-2836-2452
    3Dicle University Faculty of Medicine (1991-1998) Dicle University Faculty of Medicine, Department of Pharmacology (2001-2006) Work Experience Assistant Professor, Dicle University Faculty of Medicine, Department of Pharmacology (2008-2014) Associate Professor, Dicle University Faculty of Medicine, Department of Pharmacology (2014-2021) Professor, Dicle University Faculty of Medicine, Department of Pharmacology (2021-2024) Topics of Interest Experimental Pharmacology Regenerative Medicine Tarditional and Complementary Medicine Functional Medicine

    • Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017; 6: e1277306.

    Share This Chapter!